Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01310816 · ClinicalTrials.gov registry record · Phase 2
A Safety and Efficacy Study of Patients With Metastatic or Locally Advanced (Unresectable) Chondrosarcoma
A Phase 2 study, sponsored by Infinity Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 105
- Enrollment target
NCT01310816 is a Phase 2 study that has completed, run by Infinity Pharmaceuticals. The registered enrollment target is 105 participants.
The verdict
NCT01310816, a Phase 2 study, has completed, sponsored by Infinity Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 105 participants
- Enrollment target
Study Summary
IPI-926 is an inhibitor of the hedgehog pathway. IPI-926 may improve therapeutic outcomes in patients with Chondrosarcoma.
Interventions
- DRUG Placebo Arm
- DRUG IPI-926
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2011-02 |
| Est. Completion | 2013-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01310816
The ClinicalTrials.gov registry entry for NCT01310816 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 105 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Infinity Pharmaceuticals, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Arm is the first listed.
NCT01310816 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01310816 about?
NCT01310816 is a clinical study titled "A Safety and Efficacy Study of Patients With Metastatic or Locally Advanced (Unresectable) Chondrosarcoma". IPI-926 is an inhibitor of the hedgehog pathway. IPI-926 may improve therapeutic outcomes in patients with Chondrosarcoma.
What is the current status of trial NCT01310816?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 105 participants. The study started on 2011-02. Estimated completion is 2013-12.
What interventions are being tested in trial NCT01310816?
The interventions under investigation include: Placebo Arm (DRUG), IPI-926 (DRUG).
Who is sponsoring clinical trial NCT01310816?
This trial is sponsored by Infinity Pharmaceuticals, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.